

The impact of emotion awareness and regulation on social functioning in individuals at clinical high risk for psychosis

D. Kimhy^{1,2*}, K. E. Gill³, G. Brucato¹, J. Vakhrusheva¹, L. Arndt², J. J. Gross⁴ and R. R. Girgis^{1,2}

¹Department of Psychiatry, Columbia University, New York, NY, USA

²New York State Psychiatric Institute, New York, NY, USA

³Department of Psychology, The Catholic University of America, Washington, DC, USA

⁴Department of Psychology, Stanford University, Stanford, CA, USA

Background. Social functioning (SF) difficulties are ubiquitous among individuals at clinical high risk for psychosis (CHR), but it is not yet clear why. One possibility is suggested by the observation that effective SF requires adaptive emotion awareness and regulation. Previous reports have documented deficits in emotion awareness and regulation in individuals with schizophrenia, and have shown that such deficits predicted SF. However, it is unknown whether these deficits are present prior to the onset of psychosis or whether they are linked to SF in CHR individuals.

Method. We conducted a cross-sectional comparison of emotion awareness and regulation in 54 individuals at CHR, 87 with schizophrenia and 50 healthy controls (HC). Then, within the CHR group, we examined links between emotion awareness, emotion regulation and SF as indexed by the Global Functioning Scale: Social (Cornblatt *et al.* 2007).

Results. Group comparisons indicated significant differences between HC and the two clinical groups in their ability to identify and describe feelings, as well as the use of suppression and reappraisal emotion-regulation strategies. Specifically, the CHR and schizophrenia groups displayed comparable deficits in all domains of emotion awareness and emotion regulation. A hierarchical multiple regression analysis indicated that difficulties describing feelings accounted for 23.2% of the SF variance.

Conclusions. The results indicate that CHR individuals display substantial emotion awareness and emotion-regulation deficits, at severity comparable with those observed in individuals with schizophrenia. Such deficits, in particular difficulties describing feelings, predate the onset of psychosis and contribute significantly to poor SF in this population.

Received 28 October 2015; Revised 18 February 2016; Accepted 23 February 2016; First published online 6 April 2016

Key words: Alexithymia, clinical high risk for psychosis, emotion awareness, schizophrenia, social functioning.

Introduction

Poor social functioning (SF) is ubiquitous among individuals at clinical high risk for psychosis (CHR; Ballon *et al.* 2007; Addington *et al.* 2008; Ben-David *et al.* 2014) and has been found to be a predictor of development of psychotic symptoms (Cannon *et al.* 2008; Jang *et al.* 2011; Cornblatt *et al.* 2012; Velthorst *et al.* 2012). However, SF difficulties have also been found to be prevalent among CHR individuals who do not transition to psychosis (Yung & McGorry, 2007; Addington *et al.* 2011; Schlosser *et al.* 2012a), leading a number of authors to advocate for broadening the focus of CHR research to include functional outcomes (Yung *et al.* 2010; Cornblatt *et al.* 2012; Addington & van

der Gaag, 2015). This position is in agreement with an extensive literature pointing to SF deficits as a core liability in schizophrenia (Mueser & Tarrier, 1998). Likewise, findings from family and genetic studies of individuals with schizotypy and first-degree relatives of people with schizophrenia also suggest that SF difficulties are closely linked to the genetic vulnerability of schizophrenia (Kendler *et al.* 1996; Fanous *et al.* 2001; Tarbox & Pogue-Geile, 2011; Fanous *et al.* 2012).

Investigations of predictors of SF in CHR individuals have highlighted the detrimental impact of emotional processing difficulties, with negative symptoms (Niendam *et al.* 2006; Cornblatt *et al.* 2007; Svirskis *et al.* 2007; Willhite *et al.* 2008; Velthorst *et al.* 2010; Corcoran *et al.* 2011; Raballo & Krueger, 2011; Valmaggia *et al.* 2013; Meyer *et al.* 2014) as well as mood symptoms being particularly relevant (Cornblatt *et al.* 2007; Velthorst *et al.* 2010; Corcoran *et al.* 2011; Fulford *et al.* 2013; Kim *et al.* 2013; Meyer *et al.* 2014). Results from

* Address for correspondence: D. Kimhy, Ph.D., Department of Psychiatry, Unit #55, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.
(Email: kimhyda@nyspi.columbia.edu)

longitudinal studies are largely consistent with these findings (Bearden *et al.* 2011; Eslami *et al.* 2011; Lin *et al.* 2011; Schlosser *et al.* 2012b; Carrion *et al.* 2013; Meyer *et al.* 2014; Ziermans *et al.* 2014). When examined together with other symptom clusters, only negative symptoms significantly predicted poor SF (Corcoran *et al.* 2011; Fulford *et al.* 2013; Kim *et al.* 2013; Meyer *et al.* 2014). Similarly, links between emotion-processing deficits (i.e. anhedonia) and SF difficulties have also been documented in individuals with schizotypy and first-degree relatives of people with schizophrenia (Kerns *et al.* 2008; Karcher & Shean, 2012; Docherty *et al.* 2015), supporting the view of emotional difficulties as a core component of schizophrenia-spectrum disorders.

Findings from affective science suggest two specific candidate mechanisms relevant to SF – namely, emotion awareness and emotion regulation. Emotion awareness has been shown to be important to SF because emotions provide crucial information about the significance of social situations, and help to guide potential actions to be taken to navigate such situations (Barrett *et al.* 2001). Specifically, negative emotional experiences are thought to have particular informational value in signaling the need to adjust one's current state or activity. Because different emotions may call for the use of distinct response strategies, lack of awareness or reduced clarity of experienced feelings may make it difficult for individuals to select appropriate response strategies for dealing effectively with the social situation (Barrett *et al.* 2001), potentially resulting in poor SF. Limited emotion awareness, in particular difficulties in identifying and describing feelings, has been linked to poor SF – individuals with poor emotion awareness have been found to have fewer acquaintances and social contacts, lower rates of marriage, as well as poorer overall SF and quality of life (Kauhanen *et al.* 1993; Salminen *et al.* 1999; Kokkonen *et al.* 2001; Henry *et al.* 2006). To characterize such low emotion awareness individuals, Sifneos introduced the term alexithymia (Sifneos, 1996), a multidimensional subclinical phenomenon that afflicts about 10% of the general population (Linden *et al.* 1994; Salminen *et al.* 1999) and encompasses difficulties identifying and describing feelings, struggling to distinguish feelings from emotional arousal sensations, along with impaired symbolization and a tendency to focus on external events (Taylor *et al.* 1991).

A second candidate mechanism underlying SF is emotion regulation, which has been defined as the processes that are engaged in order to influence which emotions people have, when they have them, and how these emotions are experienced or expressed (Gross, 2007). Gross (1998) has proposed a process model of emotion regulation that distinguishes between antecedent- and response-focused strategies, with the former preceding

the full emotional response, and the latter being initiated once the response is already underway. Among non-clinical populations, use of antecedent-focused strategies such as reappraisal has been associated with enhanced SF, greater expression of positive emotion, lower negative emotional experience and higher quality of life (Gross & Muñoz, 1995; John & Gross, 2004; Brackett & Salovey, 2006). In contrast, response-focused strategies such as suppression have been linked to poorer SF, lower social support, lower satisfaction and sense of closeness to others, greater expression of negative emotion, as well as decreased well-being (Gross, 1998; Gross & John, 2003; Van't Wout *et al.* 2010). Consistent with these findings, clinical populations have been found to use significantly less reappraisal and more suppression (Campbell-Sills *et al.* 2006; Joormann & Gotlib, 2010).

Drawing upon these affective science findings, a small but growing body of research suggests that difficulties with various aspects of emotion processing may be considered a core feature of schizophrenia (Kimhy *et al.* 2012, 2014). Our group (Kimhy *et al.* 2012) and others (Van't Wout *et al.* 2007; Yu *et al.* 2011; Lincoln *et al.* 2014) have documented significantly poorer emotion awareness among individuals with schizophrenia compared with healthy individuals and not-ill siblings, although these findings are not universal (Henry *et al.* 2010). Similarly, individuals with schizophrenia have been found to be significantly more likely than healthy persons to suppress their emotions, as well as use less reappraisal (Van der Meer *et al.* 2009; Kimhy *et al.* 2012; Horan *et al.* 2013). Some studies reported no differences from healthy participants (Henry *et al.* 2008; Badcock *et al.* 2011; Perry *et al.* 2011), potentially related to a higher proportion of individuals with schizoaffective disorder. Germaine to these findings, indices of both emotion awareness and regulation were significantly correlated with poor SF in individuals with schizophrenia and difficulties describing feelings accounted for 35% of the variance in SF in this population, after controlling for age and neurocognition (Kimhy *et al.* 2012).

What is not yet clear, however, is whether difficulties with emotion awareness and emotion regulation predate the onset of psychosis, and, if yes, whether such difficulties are linked to SF. Recent reports provide preliminary support for this link – Van Rijn *et al.* (2011) found that CHR individuals displayed difficulties in identifying and verbalizing their own emotions, and such difficulties were related to social inadequacy and schizotypal traits. However, the study was limited by a relatively modest and demographically narrow sample (ages 12–18 years) and SF being measured by self-report questionnaires. More recently, Van der Velde *et al.* (2015) found that

individuals at high risk for psychosis reported greater difficulties verbalizing, identifying and analysing their own emotions compared with healthy controls (HC) and siblings. Additionally, individuals at high risk for psychosis reported lower use of reappraisal and displayed less activation in the left ventrolateral prefrontal cortex during a reappraisal task compared with HC (Van der Velde *et al.* 2015).

To address this gap in the literature, the goals of the present study were to evaluate emotion awareness and regulation in CHR individuals. Specifically, our aims were: (1) to compare emotion awareness and regulation between CHR individuals, individuals with schizophrenia and HC; and (2) among the CHR individuals, to examine the links between emotion awareness and regulation and SF. We hypothesized that CHR individuals would display emotion awareness and regulation difficulties intermediate to the schizophrenia and HC groups. We also hypothesized that emotion awareness and regulation difficulties would predict SF in CHR individuals. We will also evaluate the influence of potential covariates previously linked to SF including intelligence, depression and anxiety.

Method

Participants

Data on individuals with schizophrenia, at CHR and HC have been obtained from baseline research assessments of two separate studies conducted at the New York State Psychiatric Institute (NYSPI) at the Columbia University Medical Center. Data on CHR help-seeking individuals ($n=54$) were obtained from participants enrolled at the Center of Prevention and Evaluation, a psychosis high-risk research clinic located in the NYSPI that investigates prospectively risk and protective factors associated with the development of psychosis. Data on individuals with schizophrenia ($n=87$) were collected from individuals participating in research on emotion and autonomic regulation at the NYSPI. HC ($n=50$) were recruited by online and print advertisements. Both studies recruited participants from the greater New York City area. Data were collected between 2009 and 2015.

For the CHR individuals, the inclusion criteria were a CHR status as determined by the Structured Interview for Psychosis-Risk Syndromes (SIPS; Miller *et al.* 2003); age 14–30 years; English-speaking; and capacity to provide informed consent. The exclusion criteria included major medical or neurological disorder better accounting for symptoms; intelligence quotient (IQ) <70; significant risk of harm to self and/or others; and/or 'prodromal' symptoms temporarily related to substance or alcohol use. For the participants with

schizophrenia the inclusion criteria were age 18–50 years; English-speaking; a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of schizophrenia, schizo-affective disorder or schizophreniform disorder; and capacity to provide informed consent. The exclusion criteria were use of street drugs within the past 4 weeks (confirmed via urine toxicology test), history of neurological problems or loss of consciousness; IQ <70; and a recent history of serious suicidal/aggressive behavior. For the HC participants, the inclusion criteria were age 18–50 years and English-speaking. The exclusion criteria were a history of psychotic symptoms; a diagnosis of any DSM-IV Axis II cluster A personality disorder; IQ <70; a first-degree family member with history of psychosis; and having been adopted.

CHR status, diagnoses and symptoms

CHR status, along with severity of attenuated psychotic symptoms, were determined by the SIPS (Miller *et al.* 2003), a semi-structured interview that assess severity of 'prodromal' symptoms in four categories: positive, negative, disorganized, and general symptoms. Each item is scored on a range of 0–6, with a score of 3–5 being considered prodromal and 6 indicating threshold psychosis. A doctoral-level clinician (G.B.) with 5 years of experience administering the SIPS conducted the CHR status assessments. CHR status is determined by: (1) presence of attenuated psychotic symptoms; (2) brief intermittent psychotic symptoms; and/or (3) genetic risk (first-degree family member) with a recent decline in functioning (30% decline in Global Assessment of Functioning during the previous 12 months).

Diagnoses for all participants were determined using the Diagnostic Interview for Genetic Studies (Nurnberger *et al.* 1994), a semi-structured diagnostic interview and medical records review used to collect diagnostic and course of illness information for mood, psychotic and substance use DSM-IV Axis I disorders. The Beck Depression Inventory (BDI; Beck *et al.* 1996) was used to measure depression. Among the participants with schizophrenia, symptoms were assessed using the Scales for Assessment of Positive and Negative Symptoms (SAPS/SANS; Andreasen & Olsen, 1982).

Emotion awareness and regulation

Emotion awareness was assessed using the Toronto Alexithymia Scale (TAS-20; Bagby *et al.* 1994), with a higher score indicating poorer functioning. The TAS-20 is a self-report measure with three subscales: difficulty identifying feelings (DIF; seven items); difficulty describing feelings (DDF; five items); and externally oriented thinking (EOT; eight items). Participants are asked to

indicate on a five-point scale (from 1 = 'strongly disagree' to 5 = 'strongly agree') to what extent they agreed with each statement. The TAS-20 has a solid internal consistency (≥ 0.80) with the DIF and DDF subscales, demonstrating good reliability ($r = 0.79\text{--}0.83$). We elected to exclude the EOT subscale due to questionable reliability (Kooiman *et al.* 2002). Emotion regulation was assessed using the Emotion Regulation Questionnaire (ERQ; Gross & John, 2003), a 10-item self-report survey that provides information regarding regulation strategies of suppression (four items) and reappraisal (six items). Participants are asked to indicate on a seven-point scale (from 1 = 'strongly disagree' to 7 = 'strongly agree') to what extent they agree with each statement, with higher scores reflecting stronger endorsement of using the strategy. The ERQ has been shown to be a reliable and valid measure of emotion regulation, with an average α reliability of 0.79 for reappraisal and 0.73 for suppression. Test-retest correlations across 3 months were 0.69 for both scales (Gross & John, 2003).

SF

SF was determined using the Global Functioning Scale: Social (GFS:S; Cornblatt *et al.* 2007). The GFS:S assesses peer relationships in CHR participants based on age-appropriate social contacts inside and outside the family, romantic relationships, as well as the level of conflict the individual may or may not experience in these relationships. SF is rated on a 1–10 scale, with 1 being severe dysfunction (poor SF with no relationships) and 10 being highly sociable. The GFS:S displayed high inter-rater reliability (0.78–0.85), with preliminary data supporting its construct validity (Cornblatt *et al.* 2007).

Additional measures

A number of potential covariates were examined including intelligence, which was indexed by the Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999) along with demographic and clinical information including age, sex, race, ethnicity, medication use, depression (BDI) and anxiety (Beck Anxiety Inventory; Beck & Steer, 1993).

Procedure

Following an initial telephone screen, participants signed the informed consent forms and were assessed for eligibility. After satisfying the inclusion and exclusion criteria, participants typically completed the diagnostic and clinical assessments including measures of emotion awareness and regulation within 3 weeks of admission to their respective study as part of the baseline assessments. The CHR participants also completed the SF assessment during this period.

Data analyses

Cross-sectional group differences in emotion awareness and regulation were assessed using two-tailed *t* tests with significance levels set at $p < 0.05$, followed by one-way analyses of covariance (ANCOVAs) controlling for age. Follow-up pairwise comparisons were conducted with the Holm's sequential Bonferroni procedure used to control for type I error. Among the CHR participants, associations among emotion awareness, emotion regulation and SF were examined first using Pearson correlations, followed by partial correlations controlling for depression, anxiety and IQ. Assessment of whether emotion awareness and regulation would predict SF among the CHR participants was tested using hierarchical multiple regression analysis, with SF entered as a dependent variable, the control variables and previously identified predictors entered in block 1, the emotion awareness variables entered in block 2, and emotion regulation variables entered in block 3. We elected not to include negative symptoms as independent predictors in our analysis given such symptoms encompass to a large degree indices of SF, emotion awareness and emotion regulation, albeit with different labels. Elements of emotion awareness and emotion regulation (i.e. suppression) overlap multiple domains of negative symptoms (i.e. affective flattening, avolition–apathy). We employed a similar strategy in a previous investigation of the impact of emotion awareness and regulation on SF in individuals with schizophrenia (Kimhy *et al.* 2012). Meyer *et al.* (2014) found that the removal of social anhedonia substantially reduced the magnitude of the relationship between overall negative symptom and SF among CHR individuals [from $\beta = -0.422$ to $\beta = -0.252$; see Meyer *et al.* (2014) online Supplementary data – Tables S1a and S1b].

Results

Demographic and clinical characteristics

The sample's demographic and clinical information is presented in Table 1. There were no significant group differences in sex, ethnicity and racial background. However, the CHR individuals were significantly younger and had lower educational level, potentially related to their younger age. Of the CHR participants, 37 were medication-free (68%), three were prescribed antipsychotic medication (5%), seven were prescribed anti-depressants (13%), and seven were prescribed both (13%).

Data on IQ were available only for participants in the CHR group, indicating performance in the high average range (mean = 112.63, *s.d.* = 15.91). SF in the CHR group was not associated with age ($r = 0.03$, $p = 0.84$) or IQ ($r = 0.03$, $p = 0.88$). Likewise, there were no differences in SF in the CHR group based on sex

Table 1. Demographic and clinical information (n = 191)

	Clinical high risk (n = 54)	Schizophrenia (n = 87)	Healthy controls (n = 50)	F/t/ χ^2	p
Mean age, years (s.d.)	20.18 (3.41)	33.45 (9.47)	23.04 (4.10)	70.97	<0.001
Sex, % female	26	37	48	5.45	0.07
Ethnicity, % Hispanic	28	29	16	3.02	0.22
Race, n (%)					
Asian/Pacific Islander	5 (9)	13 (15)	8 (16)	4.43	0.82
Black/African-American	11 (20)	16 (18)	12 (24)		
Caucasian	25 (46)	39 (45)	24 (48)		
More than one race	13 (24)	19 (22)	6 (12)		
Education, n (%)					
Less than high school	6 (11)	5 (6)	1 (2)	37.87	<0.001
High school degree	17 (31)	10 (11)	1 (2)		
Some college	21 (39)	24 (28)	16 (32)		
College degree	9 (17)	33 (38)	22 (44)		
Some graduate school or higher	1 (2)	15 (17)	10 (20)		
Mean depression: BDI (s.d.)	15.48 (11.47)	11.12 (10.75)	3.02 (4.32)	20.07	<0.001
Mean anxiety: BAI (s.d.)	17.39 (14.30)	11.38 (10.64)	4.47 (6.00)	9.57	<0.001
Mean antipsychotic medication, CPE (s.d.)	0.79 (1.17)	350.50 (331.26)	0.00 (0.00)	58.42	<0.001
Antidepressant medication, % yes	26	41	0		
Mean SIPS positive symptoms (s.d.)					
Unusual thought content/delusional ideas	3.79 (0.64)				
Suspiciousness/persecutory ideas	3.27 (1.35)				
Grandiosity	1.92 (1.56)				
Perceptual abnormalities/hallucinations	3.00 (1.19)				
Disorganized communication	3.19 (0.91)				
Total	15.17 (3.39)				
Mean SIPS negative symptoms (s.d.)					
Social anhedonia	3.77 (1.34)				
Avolition	3.73 (1.30)				
Expression of emotion	2.50 (1.79)				
Experience of emotions and self	3.15 (1.60)				
Ideational richness	2.17 (1.42)				
Occupational functioning	3.81 (1.52)				
Total	19.15 (6.04)				
Mean SIPS disorganization symptoms (s.d.)					
Odd behavior or appearance	2.85 (1.21)				
Bizarre thinking	3.08 (1.08)				
Trouble with focus and attention	3.38 (1.01)				
Personal hygiene	1.77 (1.66)				
Total	11.08 (3.25)				
Mean SIPS general symptoms (s.d.)					
Sleep disturbance	3.56 (3.01)				
Dysphoric mood	3.11 (1.45)				
Motor disturbance	2.40 (1.60)				
Impaired tolerance to normal stress	4.02 (1.63)				
Total	12.71 (4.07)				

s.d., Standard deviation; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; CPE, chlorpromazine equivalents; SIPS, Structured Interview for Psychosis Risk Syndromes.

($t = 0.38$, $p = 0.70$), ethnicity ($\chi = 13.61$, $p = 0.06$) or racial background ($\chi = 26.40$, $p = 0.19$). However, suppression was significantly inversely correlated with age ($r = -0.27$, $p = 0.05$).

Among the schizophrenia group, clinical assessments indicated moderate severity of hallucinations (mean = 2.90, s.d. = 2.03) and delusions (mean = 3.00, s.d. = 1.47), along with minimal ratings of bizarre

Table 2. Comparison of emotion awareness and regulation between CHR, SCZ and HC individuals (n = 191)

	Mean (s.d.)			ANCOVA ^a			Cohen's <i>d</i> (CHR v. HC)
	SCZ (n = 87)	CHR (n = 54)	HC (n = 50)	<i>F</i>	<i>p</i>	Pairwise comparisons	
Emotion awareness							
Difficulty identifying feelings	17.13 (6.57)	19.40 (6.00)	10.87 (4.55)	27.86	<0.001	CHR, SCZ > HC	1.60
Difficulty describing feelings	13.51 (4.84)	16.04 (3.97)	10.45 (4.05)	22.95	<0.001	CHR, SCZ > HC	1.39
Emotion regulation							
Reappraisal	28.87 (8.56)	25.43 (7.00)	30.56 (7.08)	5.57	0.004	CHR, SCZ < HC	0.73
Suppression	16.21 (5.68)	17.61 (4.96)	12.06 (5.09)	15.42	<0.001	CHR, SCZ > HC	1.10

CHR, Clinical high-risk for psychosis; SCZ, schizophrenia; HC, healthy controls; ANCOVA, one-way analysis of covariance; TAS-20, Toronto Alexithymia Scale.

^aWith age as covariate; emotion awareness – indexed by the TAS-20; emotion regulation – indexed by the Emotion Regulation Questionnaire; lower TAS-20 and suppression scores indicate better functioning.

behavior and positive formal thought disorder (mean = .58, s.d. = 1.04 and mean = 1.00, s.d. = 1.28, respectively). Of the participants with schizophrenia, 37 were prescribed anti-depressants (41%) and all were prescribed antipsychotic medications, which was not significantly associated with any measures of emotion awareness or regulation.

Group comparisons of emotion awareness and regulation

Our first aim was to compare emotion awareness and regulation among individuals at CHR, with schizophrenia and HC. We conducted ANCOVAs for each of the four key variables with clinical status entered as the independent variable, the emotion awareness and regulation variables as the dependent variables, and age as a covariate. The results of these tests are presented in Table 2. For difficulties identifying feelings, there were significant group differences ($F_{2,187} = 27.86$, $p < 0.001$), with clinical status accounting for 23.4% of the variance, controlling for age. Follow-up pairwise comparisons were conducted with the Holm's sequential Bonferroni procedure used to control for type I error. The CHR group had the highest average DIF, followed closely by the schizophrenia and then HC groups.

Similarly, for difficulties describing feelings, there were significant group differences ($F_{2,187} = 22.95$, $p < 0.001$), with clinical status accounting for 20.1% of the variance, controlling for age. The CHR group had the highest mean DIF score, followed by the schizophrenia and then HC groups (Fig. 1).

For emotion regulation, there were significant group differences in the use of reappraisal ($F_{2,187} = 5.57$, $p = 0.004$), with clinical status accounting for 5.6% of the variance, controlling for age. The HC group had

significantly higher mean reappraisal scores compared with the schizophrenia and CHR groups. Likewise, for suppression there were significant group differences ($F_{2,187} = 15.42$, $p < 0.001$), with clinical status accounting for 14.2% of the variance, controlling for age. The HC group had significantly higher mean scores compared with the schizophrenia and CHR groups.

The impact of emotion awareness and regulation on SF

Next, we evaluated within the CHR group the impact of emotion awareness and regulation on SF. Data on SF were available for 43 of the 54 CHR participants. There were no significant differences in age, sex, depression, and emotion awareness and regulation between participants with and without SF data. The mean SF rating was 5.60 (s.d. = 1.44, range 2–9), with 77% of CHR individuals receiving a rating of ≤ 6 . We conducted a hierarchical step-wise multiple regression analysis with SF entered as a dependent variable; demographic variables including age, sex and education entered in block 1; and the emotion awareness and regulation variables entered in block 2. The regression analysis indicated that after controlling for age, sex and education, the model accounted for 23.2% of the variance in SF ($F_{1,41} = 12.36$, $p = 0.001$). Specifically, difficulties describing feelings contributed uniquely to the model's validity ($\beta = -0.48$, $t = -3.52$, $p = 0.001$). An exploratory analyses in the CHR group comparing emotion awareness and regulation in individuals with poor (≤ 4), medium (5–6), and high (≥ 7) SF revealed significant group differences, suggesting a dose–response relationship in which individuals with the poorest ability to describe feelings ($F_{2,40} = 5.29$, $p < 0.01$) and highest use of suppression ($F_{2,40} = 3.42$, $p = 0.04$) displayed the lowest degree of SF (see Fig. 2; Table 3).




Fig. 1. Comparison of emotion awareness and regulation in individuals with schizophrenia ($n=87$), at clinical high risk for psychosis (CHR; $n=54$) and healthy controls ($n=50$) (total $n=191$). Difficulty identifying feelings – Toronto Alexithymia Scale (TAS-20); difficulty describing feelings –TAS-20; reappraisal – Emotion Regulation Questionnaire (ERQ); suppression –ERQ. Values are means, with confidence intervals (CI) represented by vertical bars.

Discussion

To the best of our knowledge, the present study is the first investigation of the links between emotion awareness, emotion regulation and SF in individuals at CHR for psychosis. Our results indicate that compared with a non-clinical population, CHR individuals display substantial deficits in emotion awareness and regulation, as indicated by the large effect sizes for all measures. Specifically, CHR individuals reported significant difficulties identifying and describing their emotions, along with increased use of suppression and diminished use of reappraisal when attempting to regulate their emotions.

The most important finding of the present investigation is the identification of a link between poor emotional awareness and poor SF in CHR individuals, with difficulties in emotional awareness predicting 23.2% of the variance in SF. This association was accounted primarily by difficulties describing feeling and is consistent with results among individuals with

schizophrenia (Kimhy *et al.* 2012). Thus, our results extend findings from basic affective science in highlighting the fundamental role that emotion awareness plays in SF and psychopathology (Kauhanen *et al.* 1993; Sifneos, 1996; Salminen *et al.* 1999; Kokkonen *et al.* 2001; Henry *et al.* 2006). A second important finding of the present investigation relates to the severity of emotion awareness and regulation deficits in the CHR group. Specifically, the degree of CHR difficulties in these domains was comparable with those found in the schizophrenia group. These results are in agreement with recent reports (Van der Velde *et al.* 2015). Together, these findings suggest that emotion awareness deficits are present in full severity well before the onset of full psychotic symptoms. Thus, such deficits may potentially reflect an affective behavioral marker of early SF difficulties in this population. This early presentation of emotional deficits also raises key questions about their developmental origins in CHR individuals. Data from a large population-based study of




Fig. 2. Difficulty describing feelings and use of suppression in individuals at clinical high risk for psychosis (CHR; $n = 43$) with poor, medium and high social functioning and healthy controls ($n = 47$) (total $n = 90$). Social functioning – Global Functioning Scale: Social [range 1 (low) to 10 (high)]; difficulty describing feelings – Toronto Alexithymia Scale; suppression – Emotion Regulation Questionnaire. Values are means, with confidence intervals (CI) represented by vertical bars.

alexithymia among 8785 twin-pairs indicate that DDF was attributed primarily to environmental effects, with 69% of the variance explained by shared and non-shared environmental effects (15 and 54%, respectively), with genetic effects accounting for the remaining 31% (Jorgensen *et al.* 2007). Given the substantial impact of emotion awareness on SF in CHR individuals, as well as those with schizophrenia, future studies should investigate the relative effects of environmental and genetics factors on emotional awareness in CHR individuals. Likewise, the results are in agreement with findings from clinical, family and genetic studies of individuals with schizotypy, schizophrenia, and their first-degree relatives which support the view of emotion (i.e. anhedonia) and SF difficulties as core components of the schizophrenia spectrum vulnerability (Kendler *et al.* 1996; Fanous *et al.* 2001; Kerns *et al.* 2008; Tarbox & Pogue-Geile, 2011; Fanous *et al.* 2012; Karcher & Shean, 2012; Docherty *et al.* 2015).

Our findings invite a discussion about the putative neurobiological mechanism underlying poor emotional

awareness in CHR individuals and the prospect of ameliorating them. Evidence from imaging studies of individuals with schizophrenia has linked alexithymia to white matter fractional anisotropy, in particular in the corpus callosum, left superior and inferior longitudinal fasciculi, inferior occipitofrontal fasciculus, anterior and posterior thalamic radiation, and the precuneus (Kubota *et al.* 2012). Alexithymia has also been linked to lower gray matter volume in the left supra-marginal gyrus (Kubota *et al.* 2011), a region involved in language processing. Consistent with these findings, lower gray matter volume in this region has been documented among CHR individuals (Koutsouleris *et al.* 2009) along with reduced activation (Fusar-Poli *et al.* 2011), suggesting a potential region of interest underlying poor emotional awareness in this population. Increasing patients' abilities to identify and describe emotions are an important component of many contemporary cognitive and behavioral psychotherapies (Greenberg & Pascual-Leone, 2006) and preliminary evidence suggests feasibility and efficacy of improving

Table 3. Emotion awareness and regulation in individuals at clinical high risk for psychosis – associations with social functioning^a

	Difficulty identifying feelings	Difficulty describing feelings	Reappraisal	Suppression	Social functioning
Difficulty identifying feelings (TAS-20)	–	0.46****	–0.14	0.25	–0.01
Difficulty describing feelings (TAS-20)	0.46***	–	–0.26*	0.57****	–0.48***
Reappraisal (ERQ)	–0.11	–0.24*	–	0.17	0.10
Suppression (ERQ)	0.20	0.56****	–0.13	–	–0.37**
Social functioning (GFS:S)	–0.01	–0.48***	0.10	–0.37**	–

TAS-20, Toronto Alexithymia Scale; ERQ, Emotion Regulation Questionnaire; GFS:S, Global Functioning Scale: Social.

^a Zero-order correlations are presented above the diagonal. Partial correlations controlling for age are presented below the diagonal. Lower TAS-20 and suppression scores indicate better functioning.

* $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$, **** $p < 0.001$.

alexithymia (Fukunishi *et al.* 1997; Beresnevaite, 2000; Honkalampi *et al.* 2000). Consistent with this view, evidence from basic affective science studies demonstrates that the act of labeling emotions in response to affective stimuli attenuates emotional responses (Lieberman *et al.* 2007; Niles *et al.* 2015). Specifically, among non-clinical individuals, labeling one's emotional experiences has been found to activate the right ventrolateral prefrontal cortex, resulting in reduced amygdala activation (Hariri *et al.* 2000; Narumoto *et al.* 2000; Gorno-Tempini *et al.* 2001; Hariri *et al.* 2003). Future studies should aim to develop and test treatments to address emotion awareness difficulties in CHR individuals.

Our results have additional implications for future research of schizophrenia and CHR individuals. To date, research of social cognition in these clinical populations has focused primarily on a number of domains including perception of emotion in others, theory of mind, social perception and attribution style (Pinkham *et al.* 2014). In contrast, the way individuals perceive their own emotions and how they process and regulate them have received relatively little attention. Given our results, along with previous reports (Kimhy *et al.* 2012, 2014; O'Driscoll *et al.* 2014; Van der Velde *et al.* 2015), emotion awareness and regulation may serve as promising targets for investigations relating to social cognition and SF in individuals with CHR and schizophrenia. The strengths of the present investigation include the rigorous diagnostic and clinical assessments and the use of a psychometrically sound clinician-based measure that assess SF separately from role functioning and symptom severity (Cornblatt *et al.* 2007). One potential limitation of the present study is the moderate CHR sample size. Another limitation is the use of self-report measures to index emotion regulation and the focus on only two emotion-regulation strategies. Also,

data on a number of potential covariates were available only for the CHR group (e.g. intelligence).

In summary, our results indicate that CHR individuals display substantial emotion-awareness and emotion-regulation deficits, at severity comparable with those observed in individuals with schizophrenia. Such deficits, in particular difficulties describing feelings, predate the onset of psychosis and contribute significantly to poor SF in this population.

Acknowledgements

This work was supported by grants 1K23MH077653 and 1R21MH096132 (to D.K.) and 1R01MH093398 from the National Institute of Mental Health, Bethesda, MD, USA.

Declaration of Interest

None.

References

- Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinsen R (2011). At clinical high risk for psychosis: outcome for nonconverters. *American Journal of Psychiatry* **168**, 800–805.
- Addington J, Penn D, Woods SW, Addington D, Perkins DO (2008). Social functioning in individuals at clinical high risk for psychosis. *Schizophrenia Research* **99**, 119–124.
- Addington J, van der Gaag M (2015). Psychosocial treatments for clinical high risk individuals. *Schizophrenia Bulletin* **41**, 22.
- Andreasen NC, Olsen S (1982). Negative v positive schizophrenia. Definition and validation. *Archives of General Psychiatry* **39**, 789–794.

- Badcock JC, Paulik G, Maybery MT (2011). The role of emotion regulation in auditory hallucinations. *Psychiatry Research* **185**, 303–308.
- Bagby RM, Taylor GJ, Parker JD (1994). The twenty-item Toronto Alexithymia Scale – II. Convergent, discriminant, and concurrent validity. *Journal of Psychosomatic Research* **38**, 33–40.
- Ballon JS, Kaur T, Marks II, Cadenhead KS (2007). Social functioning in young people at risk for schizophrenia. *Psychiatry Research* **151**, 29–35.
- Barrett LF, Gross J, Christensen TC, Benvenuto M (2001). Knowing what you're feeling and knowing what to do about it: mapping the relation between emotion differentiation and emotion regulation. *Cognition and Emotion* **15**, 713–724.
- Bearden CE, Wu KN, Caplan R, Cannon TD (2011). Thought disorder and communication deviance as predictors of outcome in youth at clinical high risk for psychosis. *Journal of the American Academy of Child and Adolescent Psychiatry* **50**, 669–680.
- Beck AT, Steer RA (1993). *Beck Anxiety Inventory Manual*. Harcourt Brace and Company: San Antonio, TX.
- Beck AT, Steer RA, Brown GK (1996). *Beck Depression Inventory II Manual*. The Psychological Corporation: San Antonio, TX.
- Ben-David S, Birnbaum ML, Eilenberg ME, DeVyllder JE, Gill KE, Schienle J, Azimov N, Lukens EP, Davidson L, Corcoran CM (2014). The subjective experience of youths at clinically high risk of psychosis: a qualitative study. *Psychiatric Services* **65**, 1499–1501.
- Beresnevaite M (2000). Exploring the benefits of group psychotherapy in reducing alexithymia in coronary heart disease patients: a preliminary study. *Psychotherapy and Psychosomatics* **69**, 117–122.
- Brackett MA, Salovey P (2006). Measuring emotional intelligence with the Mayer–Salovey–Caruso emotional intelligence test. *Psicothema* **18** (Suppl.), 34–41.
- Campbell-Sills L, Barlow DH, Brown TA, Hofmann SG (2006). Acceptability and suppression of negative emotion in anxiety and mood disorders. *Emotion* **6**, 587–595.
- Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. *Archives of General Psychiatry* **65**, 28–37.
- Carrion RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH, Olvet DM, Correll CU, Cornblatt BA (2013). Prediction of functional outcome in individuals at clinical high risk for psychosis. *JAMA Psychiatry* **70**, 1133–1142.
- Corcoran CM, Kimhy D, Parrilla-Escobar MA, Cressman VL, Stanford AD, Thompson J, David SB, Crumbley A, Schobel S, Moore H, Malaspina D (2011). The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis. *Psychological Medicine* **41**, 251–261.
- Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, Cannon TD (2007). Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. *Schizophrenia Bulletin* **33**, 688–702.
- Cornblatt BA, Carrion RE, Addington J, Seidman L, Walker EF, Cannon TD, Cadenhead KS, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Heinssen R, Lencz T (2012). Risk factors for psychosis: impaired social and role functioning. *Schizophrenia Bulletin* **38**, 1247–1257.
- Docherty AR, Sponheim SR, Kerns JG (2015). Self-reported affective traits and current affective experiences of biological relatives of people with schizophrenia. *Schizophrenia Research* **161**, 340–344.
- Eslami A, Jahshan C, Cadenhead KS (2011). Disorganized symptoms and executive functioning predict impaired social functioning in subjects at risk for psychosis. *Journal of Neuropsychiatry and Clinical Neuroscience* **23**, 457–460.
- Fanous A, Gardner C, Walsh D, Kendler KS (2001). Relationship between positive and negative symptoms of schizophrenia and schizotypal symptoms in nonpsychotic relatives. *Archives of General Psychiatry* **58**, 669–673.
- Fanous AH, Zhou B, Aggen SH, Bergen SE, Amdur RL, Duan J, Sanders AR, Shi J, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Freedman R, Dudbridge F, Holmans PA, Ripke S, Gejman PV, Kendler KS, Levinson DF, Schizophrenia Psychiatric Genome-Wide Association Study C (2012). Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms. *American Journal of Psychiatry* **169**, 1309–1317.
- Fukunishi I, Kikuchi M, Takubo M (1997). Changes in scores on alexithymia over a period of psychiatric treatment. *Psychological Reports* **80**, 483–489.
- Fulford D, Niendam TA, Floyd EG, Carter CS, Mathalon DH, Vinogradov S, Stuart BK, Loewy RL (2013). Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms. *Schizophrenia Research* **147**, 125–131.
- Fusar-Poli P, Broome MR, Woolley JB, Johns LC, Tabraham P, Bramon E, Valmaggia L, Williams SC, McGuire P (2011). Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: longitudinal VBM-fMRI study. *Journal of Psychiatric Research* **45**, 190–198.
- Gorno-Tempini ML, Pradelli S, Serafini M, Pagnoni G, Baraldi P, Porro C, Nicoletti R, Umida C, Nichelli P (2001). Explicit and incidental facial expression processing: an fMRI study. *NeuroImage* **14**, 465–473.
- Greenberg LS, Pascual-Leone A (2006). Emotion in psychotherapy: a practice-friendly research review. *Journal of Clinical Psychology* **62**, 611–630.
- Gross JJ (1998). Antecedent- and response-focused emotion regulation: divergent consequences for experience, expression, and physiology. *Journal of Personality and Social Psychology* **74**, 224–237.
- Gross JJ (2007). *Emotion Regulation: Conceptual Foundations*. Guilford Press: New York.
- Gross JJ, John OP (2003). Individual differences in two emotion regulation processes: implications for affect, relationships, and well-being. *Journal of Personality and Social Psychology* **85**, 348–362.
- Gross JJ, Muñoz RF (1995). Emotion regulation and mental health. *Clinical Psychology: Science and Practice* **2**, 151–164.

- Hariri AR, Bookheimer SY, Mazziotta JC (2000). Modulating emotional responses: effects of a neocortical network on the limbic system. *Neuroreport* **11**, 43–48.
- Hariri AR, Mattay VS, Tessitore A, Fera F, Weinberger DR (2003). Neocortical modulation of the amygdala response to fearful stimuli. *Biological Psychiatry* **53**, 494–501.
- Henry JD, Bailey PE, von Hippel C, Rendell PG, Lane A (2010). Alexithymia in schizophrenia. *Journal of Clinical and Experimental Neuropsychology* **32**, 890–897.
- Henry JD, Phillips LH, Maylor EA, Hosie J, Milne AB, Meyer C (2006). A new conceptualization of alexithymia in the general adult population: implications for research involving older adults. *Journal of Psychosomatic Research* **60**, 535–543.
- Henry JD, Rendell PG, Green MJ, McDonald S, O'Donnell M (2008). Emotion regulation in schizophrenia: affective, social, and clinical correlates of suppression and reappraisal. *Journal of Abnormal Psychology* **117**, 473–478.
- Honkalampi K, Hintikka J, Saarinen P, Lehtonen J, Viinamaki H (2000). Is alexithymia a permanent feature in depressed patients? Results from a 6-month follow-up study. *Psychotherapy and Psychosomatics* **69**, 303–308.
- Horan WP, Hajcak G, Wynn JK, Green MF (2013). Impaired emotion regulation in schizophrenia: evidence from event-related potentials. *Psychological Medicine* **43**, 2377–2391.
- Jang JH, Shin NY, Shim G, Park HY, Kim E, Jang GE, Kwon SJ, Hur JW, An SK, Kwon JS (2011). Longitudinal patterns of social functioning and conversion to psychosis in subjects at ultra-high risk. *Australian and New Zealand Journal of Psychiatry* **45**, 763–770.
- John OP, Gross JJ (2004). Healthy and unhealthy emotion regulation: personality processes, individual differences, and life span development. *Journal of Personality* **72**, 1301–1333.
- Jormann J, Gotlib IH (2010). Emotion regulation in depression: relation to cognitive inhibition. *Cognition and Emotion* **24**, 281–298.
- Jorgensen MM, Zachariae R, Skytthe A, Kyvik K (2007). Genetic and environmental factors in alexithymia: a population-based study of 8,785 Danish twin pairs. *Psychotherapy and Psychosomatics* **76**, 369–375.
- Karcher N, Shean G (2012). Magical ideation, schizotypy and the impact of emotions. *Psychiatry Research* **197**, 36–40.
- Kauhanen J, Kaplan GA, Julkunen J, Wilson TW, Salonen JT (1993). Social factors in alexithymia. *Comprehensive Psychiatry* **34**, 330–335.
- Kendler KS, Thacker L, Walsh D (1996). Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia. *Schizophrenia Bulletin* **22**, 511–520.
- Kerns JG, Docherty AR, Martin EA (2008). Social and physical anhedonia and valence and arousal aspects of emotional experience. *Journal of Abnormal Psychology* **117**, 735–746.
- Kim KR, Song YY, Park JY, Lee EH, Lee M, Lee SY, Kang JI, Lee E, Yoo SW, An SK, Kwon JS (2013). The relationship between psychosocial functioning and resilience and negative symptoms in individuals at ultra-high risk for psychosis. *Australian and New Zealand Journal of Psychiatry* **47**, 762–771.
- Kimhy D, Vakhrusheva J, Jobson-Ahmed L, TARRIER N, Malaspina D, Gross JJ (2012). Emotion awareness and regulation in individuals with schizophrenia: implications for social functioning. *Psychiatry Research* **200**, 193–201.
- Kimhy D, Vakhrusheva J, Khan S, Chang RW, Hansen MC, Ballon JS, Malaspina D, Gross JJ (2014). Emotional granularity and social functioning in individuals with schizophrenia: an experience sampling study. *Journal of Psychiatric Research* **53**, 141–148.
- Kokkonen P, Karvonen JT, Veijola J, Laksy K, Jokelainen J, Jarvelin MR, Joukamaa M (2001). Prevalence and sociodemographic correlates of alexithymia in a population sample of young adults. *Comprehensive Psychiatry* **42**, 471–476.
- Kooiman CG, Spinhoven P, Trijsburg RW (2002). The assessment of alexithymia: a critical review of the literature and a psychometric study of the Toronto Alexithymia Scale-20. *Journal of Psychosomatic Research* **53**, 1083–1090.
- Koutsouleris N, Schmitt GJ, Gaser C, Bottlender R, Scheuerecker J, McGuire P, Burgermeister B, Born C, Reiser M, Moller HJ, Meisenzahl EM (2009). Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. *British Journal of Psychiatry* **195**, 218–226.
- Kubota M, Miyata J, Hirao K, Fujiwara H, Kawada R, Fujimoto S, Tanaka Y, Sasamoto A, Sawamoto N, Fukuyama H, Takahashi H, Murai T (2011). Alexithymia and regional gray matter alterations in schizophrenia. *Neuroscience Research* **70**, 206–213.
- Kubota M, Miyata J, Sasamoto A, Kawada R, Fujimoto S, Tanaka Y, Sawamoto N, Fukuyama H, Takahashi H, Murai T (2012). Alexithymia and reduced white matter integrity in schizophrenia: a diffusion tensor imaging study on impaired emotional self-awareness. *Schizophrenia Research* **141**, 137–143.
- Lieberman MD, Eisenberger NI, Crockett MJ, Tom SM, Pfeifer JH, Way BM (2007). Putting feelings into words: affect labeling disrupts amygdala activity in response to affective stimuli. *Psychological Science* **18**, 421–428.
- Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, Broussard C, Pantelis C, Yung AR (2011). Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. *Schizophrenia Research* **132**, 1–7.
- Lincoln TM, Hartmann M, Kother U, Moritz S (2014). Do people with psychosis have specific difficulties regulating emotions? *Clinical Psychology and Psychotherapy* **22**, 637–646.
- Linden W, Wen F, Poulhus DL (1994). Measuring alexithymia: reliability, validity, and prevalence. In *Advances in Personality Assessment* (ed. J. Butcher and C. Spielberger), pp. 51–95. Lawrence Erlbaum Associates: Hillsdale, NJ.
- Meyer EC, Carrion RE, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Heinssen R, Seidman LJ, Group N (2014). The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study. *Schizophrenia Bulletin* **40**, 1452–1461.
- Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearson GD, Woods SW (2003). Prodromal assessment with the Structured Interview for Prodromal Syndromes and the

- Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophrenia Bulletin* **29**, 703–715.
- Mueser KT, Tarrrier N (1998). *Handbook of Social Functioning in Schizophrenia*. Allyn & Bacon: Boston, MA.
- Narumoto J, Yamada H, Iidaka T, Sadato N, Fukui K, Itoh H, Yonekura Y (2000). Brain regions involved in verbal or non-verbal aspects of facial emotion recognition. *Neuroreport* **11**, 2571–2576.
- Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O'Brien M, Nuechterlein KH, Green MF, Cannon TD (2006). Neurocognitive performance and functional disability in the psychosis prodrome. *Schizophrenia Research* **84**, 100–111.
- Niles AN, Craske MG, Lieberman MD, Hur C (2015). Affect labeling enhances exposure effectiveness for public speaking anxiety. *Behaviour Research and Therapy* **68**, 27–36.
- Nurnberger Jr. JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T (1994). Diagnostic Interview for Genetic Studies. Rationale, unique features, and training. NIMH Genetics Initiative. *Archives of General Psychiatry* **51**, 849–859; discussion 863–864.
- O'Driscoll C, Laing J, Mason O (2014). Cognitive emotion regulation strategies, alexithymia and dissociation in schizophrenia, a review and meta-analysis. *Clinical Psychology Reviews* **34**, 482–495.
- Perry Y, Henry JD, Grisham JR (2011). The habitual use of emotion regulation strategies in schizophrenia. *British Journal of Clinical Psychology* **50**, 217–222.
- Pinkham AE, Penn DL, Green MF, Buck B, Healey K, Harvey PD (2014). The Social Cognition Psychometric Evaluation study: results of the expert survey and RAND panel. *Schizophrenia Bulletin* **40**, 813–823.
- Raballo A, Krueger J (2011). Phenomenology of the social self in the prodrome of psychosis: from perceived negative attitude of others to heightened interpersonal sensitivity. *European Psychiatry* **26**, 532–533.
- Salminen JK, Saarijarvi S, Aarela E, Toikka T, Kauhanen J (1999). Prevalence of alexithymia and its association with sociodemographic variables in the general population of Finland. *Journal of Psychosomatic Research* **46**, 75–82.
- Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, Bearden CE, Cannon TD (2012a). Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. *Schizophrenia Bulletin* **38**, 1225–1233.
- Schlosser DA, Pearson R, Perez VB, Loewy RL (2012b). Environmental risk and protective factors and their influence on the emergence of psychosis. *Adolescent Psychiatry* **2**, 163–171.
- Sifneos PE (1996). Alexithymia: past and present. *American Journal of Psychiatry* **153**, 137–142.
- Svirskis T, Korkeila J, Heinimaa M, Huttunen J, Ilonen T, Ristkari T, Hietala J, Syvalahti E, McGlashan T, Vahlberg T, Salokangas RK (2007). Quality of life and functioning ability in subjects vulnerable to psychosis. *Comprehensive Psychiatry* **48**, 155–160.
- Tarbox SI, Pogue-Geile MF (2011). A multivariate perspective on schizotypy and familial association with schizophrenia: a review. *Clinical Psychology Review* **31**, 1169–1182.
- Taylor GJ, Bagby RM, Parker JD (1991). The alexithymia construct. A potential paradigm for psychosomatic medicine. *Psychosomatics* **32**, 153–164.
- Valmaggia LR, Stahl D, Yung AR, Nelson B, Fusar-Poli P, McGorry PD, McGuire PK (2013). Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. *Psychological Medicine* **43**, 2311–2325.
- Van der Meer L, van't Wout M, Aleman A (2009). Emotion regulation strategies in patients with schizophrenia. *Psychiatry Research* **170**, 108–113.
- Van der Velde J, Swart M, van Rijn S, van der Meer L, Wunderink L, Wiersma D, Krabbendam L, Bruggeman R, Aleman A (2015). Cognitive alexithymia is associated with the degree of risk for psychosis. *PLOS ONE* **10**, e0124803.
- Van Rijn S, Schothorst P, Wout M, Sprong M, Ziermans T, van Engeland H, Aleman A, Swaab H (2011). Affective dysfunctions in adolescents at risk for psychosis: emotion awareness and social functioning. *Psychiatry Research* **187**, 100–105.
- Van't Wout M, Aleman A, Bermond B, Kahn RS (2007). No words for feelings: alexithymia in schizophrenia patients and first-degree relatives. *Comprehensive Psychiatry* **48**, 27–33.
- Van't Wout M, Chang LJ, Sanfey AG (2010). The influence of emotion regulation on social interactive decision-making. *Emotion* **10**, 815–821.
- Velthorst E, Nieman DH, Linszen D, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, French P, Stevens H, Schultze-Lutter F, Klosterkötter J, Ruhrmann S (2010). Disability in people clinically at high risk of psychosis. *British Journal of Psychiatry* **197**, 278–284.
- Velthorst E, Nieman DH, Veling W, Klaassen RM, Dragt S, Rietdijk J, Ising H, Wunderink L, Linszen DH, de Haan L, van der Gaag M (2012). Ethnicity and baseline symptomatology in patients with an at risk mental state for psychosis. *Psychological Medicine* **42**, 247–256.
- Wechsler D (1999). *Wechsler Abbreviated Scale of Intelligence*. Pearson: San Antonio, TX.
- Willhite RK, Niendam TA, Bearden CE, Zinberg J, O'Brien MP, Cannon TD (2008). Gender differences in symptoms, functioning and social support in patients at ultra-high risk for developing a psychotic disorder. *Schizophrenia Research* **104**, 237–245.
- Yu S, Li H, Liu W, Zheng L, Ma Y, Chen Q, Chen Y, Yu H, Lu Y, Pan B, Wang W (2011). Alexithymia and personality disorder functioning styles in paranoid schizophrenia. *Psychopathology* **44**, 371–378.
- Yung AR, McGorry PD (2007). Prediction of psychosis: setting the stage. *British Journal of Psychiatry Supplement* **51**, s1–s8.
- Yung AR, Nelson B, Thompson A, Wood SJ (2010). The psychosis threshold in ultra high risk (prodromal) research: is it valid? *Schizophrenia Research* **120**, 1–6.
- Ziermans T, de Wit S, Schothorst P, Sprong M, van Engeland H, Kahn R, Durston S (2014). Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up. *PLOS ONE* **9**, e93994.